Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label long-term extension of apremilast in pediatric Behçet disease with active oral ulcers
MOH_2023-05-08_012615Phase 3Not yet recruiting
- Sponsor
- Amgen
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of apremilast in Behçet's disease (BD), sponsored by Amgen. Primary endpoint: Long-term safety of apremilast. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
apremilast
03
Conditions
Behçet's disease (BD)
Beyond the preview
Go deeper on MOH_2023-05-08_012615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-05-08_012615.